Hydromer Reports Q1 Revenue Decline Amid Strategic Reinvestment
Medical coatings company Hydromer experienced a revenue and earnings decrease in Q1 2025, yet remains committed to strategic investments and long-term growth in the medical device technology sector.
Hydromer, Inc. reported preliminary unaudited financial results for the first quarter of 2025, revealing a modest decline in revenue and profitability while maintaining a strategic focus on future development.
The company's first-quarter revenue reached $1.0 million, a 9% decrease from the $1.1 million recorded in the same period of 2024. CEO Michael Torti attributed the decline to legacy customer attrition and typical onboarding delays in the medical coatings industry.
Net income for the quarter was $112,000, representing a 64% reduction compared to the previous year. The decrease stems from lower revenue and increased operating expenses related to product development and infrastructure investments.
Despite financial challenges, Hydromer remains dedicated to its long-term growth strategy. The company is prioritizing product pipeline enhancement and expansion into higher-value markets. Management has also decided to defer a comprehensive U.S. GAAP audit, citing capital conservation as a primary consideration.
Hydromer continues to position itself as an innovative surface modification and coating solutions provider, serving businesses across medical, technological, and industrial sectors. The company maintains its commitment to operational efficiency, customer partnerships, and next-generation technology development.